Abstract: The present invention provides a compound or a pharmaceutically acceptable salt, isomer, prodrug, polymorph or solvate thereof, and a preparation method therefor and use thereof. The compound provided in the present invention has comparable or superior activity to Elagolix as a GnRHR antagonist in calcium flux assays and have better pharmacokinetic properties.

Abstract: The solution provides a method for separating a Chinese traditional medicine composition. To explain a pharmacological effect mechanism of a medicine made of two or more components and scientific content in rules of compatibility among components of a compound medicine, systematic researches on the material basis is very necessary. Accordingly, deep researches are done on chemical components of the pharmaceutical composition in the solution, and eight compounds are separated, which are 10-O-(p-hydroxycinnamoyl)-adoxosidic acid, aloe-emodin-8-O-?-D-glucopyranoside, quercitrin, matairesinol-4?-O-glucoside, liquiritin apioside, epi-vogeloside, vogeloside and ethyl caffeate, which provides a new quality control method for the composition in the solution.

Abstract: The disclosure provides a method for separating eighteen components in a traditional Chinese medicine composition, including: (1) preparing the traditional Chinese medicine composition into a total extract of the traditional Chinese medicine composition, separating by resin through sequentially eluting with water, 10% ethanol and 30% ethanol, and collecting the 30% ethanol eluate to obtain a 30% ethanol extract; (2) adding the 30% ethanol extract to a reverse phase silica gel ODS-AQ-HG, and separating in a medium pressure separation column to obtain differently numbered elution dry pastes; (3) dissolving the differently numbered elution dry paste with 30% methanol as a solvent, and passing the solution through a 0.45 ?m microporous membrane, carrying out a primary separation by high performance liquid chromatography and collecting chromatographic peaks with different retention times, and further purifying by high performance liquid chromatography; finally obtaining the components of eighteen components.

Abstract: A method for determining the content of menthol in a traditional Chinese medicine composition. The traditional Chinese medicine composition consists of the following medicinal materials: Fructus Forsythia, Flos Lonicerae, Radix Isatidis, Semen Armeniacae Amarum, menthol, Herba Houttuyniae, rheum, Herba Pogostemonis, Rhizoma Dryopteris Crassirhizomae, Rhodiola rosea L., Herba Ephedrae, Radix Glycyrrhizae and gypsum. In the method for determining the content, the content of the menthol in the composition is determined by gas chromatography to effectively control the content of menthol in the composition, and the method can save energy and reduce the costs for analysis.

Abstract: The present invention discloses a type-G crystal form of fenolamine, a preparation method thereof, and a composition and use thereof. In particular, disclosed is a type-G crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-G fenolamine crystal form in solid state; a method for preparing the solid of type-G crystal form; and use of the solid of the type-G fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).

Abstract: The present invention discloses a type-B crystal form of fenolamine, a preparation method thereof, and a composition and use thereof, more particularly a type-B crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-B fenolamine crystal form in solid state; a method for preparing the solid of type-B crystal form; and use of the solid of the type-B fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).

Abstract: The present invention discloses a type-B crystal form of fenolamine, a preparation method thereof, and a composition and use thereof, more particularly a type-B crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-B fenolamine crystal form in solid state; a method for preparing the solid of type-B crystal form; and use of the solid of the type-B fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).

Abstract: The present invention involves the application of Semen Ziziphi Spinosae oil in the preparation of drugs for treating medicinal insomnia. Semen Ziziphi Spinosae oil has a therapeutic effect on insomnia caused by ephedrine, prednisone and other drugs, and Semen Ziziphi Spinosae oil that is prepared within the pressing temperature of 80 to 100° C. has the best efficacy for treating medicinal insomnia.

Abstract: The disclosure provides a method for separating eighteen components in a traditional Chinese medicine composition, including: (1) preparing the traditional Chinese medicine composition into a total extract of the traditional Chinese medicine composition, separating by resin through sequentially eluting with water, 10% ethanol and 30% ethanol, and collecting the 30% ethanol eluate to obtain a 30% ethanol extract; (2) adding the 30% ethanol extract to a reverse phase silica gel ODS-AQ-HG, and separating in a medium pressure separation column to obtain differently numbered elution dry pastes; (3) dissolving the differently numbered elution dry paste with 30% methanol as a solvent, and passing the solution through a 0.45 ?m microporous membrane, carrying out a primary separation by high performance liquid chromatography and collecting chromatographic peaks with different retention times, and further purifying by high performance liquid chromatography; finally obtaining the components of eighteen components.

Abstract: The solution provides a method for separating a Chinese traditional medicine composition. To explain a pharmacological effect mechanism of a medicine made of two or more components and scientific content in rules of compatibility among components of a compound medicine, systematic researches on the material basis is very necessary. Accordingly, deep researches are done on chemical components of the pharmaceutical composition in the solution, and eight compounds are separated, which are 10-O-(p-hydroxycinnamoyl)-adoxosidic acid, aloe-emodin-8-O-?-D-glucopyranoside, quercitrin, matairesinol-4-O-glucoside, liquiritin apioside, epi-vogeloside, vogeloside and ethyl caffeate, which provides a new quality control method for the composition in the solution.

Abstract: The present invention discloses a type-G crystal form of fenolamine, a preparation method thereof, and a composition and use thereof. In particular, disclosed is a type-G crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-G fenolamine crystal form in solid state; a method for preparing the solid of type-G crystal form; and use of the solid of the type-G fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).

Abstract: The present invention involves the application of Semen Ziziphi Spinosae oil in the preparation of drugs for treating medicinal insomnia. Semen Ziziphi Spinosae oil has a therapeutic effect on insomnia caused by ephedrine, prednisone and other drugs, and Semen Ziziphi Spinosae oil that is prepared within the pressing temperature of 80 to 100° C. has the best efficacy for treating medicinal insomnia.

Abstract: The present invention relates to a pyrrole-substituted indolone derivative, a preparation method therefor, a composition comprising the derivative, and use thereof. The pyrrole-substituted indolone derivative has a structure shown in formula (I) below. The present invention further relates to use of the pyrrole-substituted indolone derivative for treating receptor tyrosine kinase-mediated diseases, and to a pharmaceutical composition comprising compounds having such a structure for treating related diseases such as tumors.

Abstract: The present invention relates to a pyrrole-substituted indolone derivative, a preparation method therefor, a composition comprising the derivative, and use thereof. The pyrrole-substituted indolone derivative has a structure shown in formula (I) below. The present invention further relates to use of the pyrrole-substituted indolone derivative for treating receptor tyrosine kinase-mediated diseases, and to a pharmaceutical composition comprising compounds having such a structure for treating related diseases such as tumors.

Abstract: (?)-(S)-3-(3?-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels.

Abstract: The biphenyl acetate is biphenyl acetic ammonia butantriol salt, which is obtained by reacting biphenyl acetic acid with ammonia butantriol in organic solvent. The salt is adapted to be used for producing analgesic, anti-inflammatory and antithermic medicines.